Free public records show ANI Pharmaceuticals in 9 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: SEC EDGAR, Company filings, CIK 1023024. Retrieved 13 Nov 2026.
58 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
13 recalls since 2015 (13 for medicines)
Source: openFDA, FDA enforcement reports (recalls) naming the firm, since 2015. Retrieved 13 Nov 2026.
Annual reports and other filings with the US Securities and Exchange Commission.
Source: SEC EDGAR, Company filings, CIK 1023024.
Markets we cover where free public records show ANI Pharmaceuticals: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets ANI Pharmaceuticals is in.
Stories on the topics ANI Pharmaceuticals works in.
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Read
Drug-resistant infections already kill over a million people a year. Faster testing helps doctors pick the…
Read
Needleless connectors protect staff from needle injuries, but if not cleaned they can let germs into the…
Read